NCT06180863 2023-12-26
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT05371860 2023-09-22
Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response
Cedars-Sinai Medical Center
Phase 2 Withdrawn
NCT01843179 2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2 Withdrawn
NCT01956513 2013-10-08
ADC
Centre Jean Perrin
Phase NA Withdrawn